<DOC>
	<DOCNO>NCT01728779</DOCNO>
	<brief_summary>Patients metastatic lesion lung , liver , bone candidate treatment . Within three week initial treatment planning , 15 Gy dose ( per lesion site ) SBRT administer . Prior SBRT , patient initiate Nelfinavir oral therapy twice daily 7 day . Once SBRT complete , patient repeat Nelfinavir therapy additional 7 day total 14 day treatment .</brief_summary>
	<brief_title>Stereotactic Body Radiation With Nelfinavir Oligometastases</brief_title>
	<detailed_description>The use radiation therapy treat metastatic tumor well establish promise data emerge use SBRT metastatic disease . However , use single large fraction concurrent radiosensitizer propose proven benefit . This investigation aim confirm safety efficacy SBRT use concurrently radiosensitizer set oligometastatic disease . The dose select chosen belief safe effective base prior experience SBRT lung cancer , pancreatic cancer brain radiosurgery . All patient treat single fraction ( per lesion site ) , target lesion concurrently radiosensitizer Nelfinavir . On basis preclinical evidence , propose phase II study Nelfinavir combine SBRT patient oligometastatic disease . Because standard dose Nelfinavir HIV patient know safe inhibit phosphorylation Akt decrease tumor hypoxia , propose study conjunction 15 Gy dose SBRT . Experience single-fraction pulmonary pancreas SBRT provide useful dose trial . With publish data establish relative safety large single-fraction SBRT lung pancreas , decide proceed determine safety 15 Gy SBRT concurrently radiosensitizer Nelfinavir . Once establish , propose continue enroll patient study dose determine efficacy type therapy . The propose study represent inform estimate base current knowledge SBRT dose administer currently approve image-guided protocol ( brain , base skull , cervico-thoracic spine , pancreas liver ) . This study refine current understanding single fraction radiation tolerance normal tissue , thereby make possible treat future patient safely aggressively .</detailed_description>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Inclusion Criteria Patient 's tumor ( ) treat ( ) ≤ 5.0 cm ≤250 cm3 Patient must metastasis one follow site : bone , liver , lymph node and/or lung . No five lesion treat . Histological confirmation malignancy ( primary metastatic tumor ) . Patient may prior therapy allow aside prior radiotherapy treatment site ( see exclusion criterion 5.2.3 ) . Patient must ≥ 18 year age . Patient must life expectancy ≥ 9 month . Patient must ECOG performance status ≤ 2 . Patient must normal organ marrow function . Patient must ability understand willingness sign write informed consent document . Patients chemotherapy radiotherapy within 2 week prior enter study Patients receive investigational agent Pateitnw ho prior radiotherapy treatment site ( ) Patients take drug contraindicate nelfinavir , include follow : Amiodarone , Quinidine , Rifampin , Dihydroergotamine , Ergonovine , Ergotamine , Methylergonovine , Hypericum perforatum ( St. John 's wort ) , Lovastatin , Simvastatin , Pimozide , Midazolam , Triazolam Women child bear potential refuse take pregnancy test prior treatment Participation another concurrent treatment protocol treat protocol 3 month treatment protocol end Pregnant woman Inability understand inform consent document Inability sign inform consent document Poor liver function suggestive cirrhosis steatohepatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>